Histology versus molecular surveillance: claims and evidence

Many novel biomarkers are targeting detection of subclinical rejection to challenge the need for and replace the cost of protocol biopsies. There are 2 separate questions: Can we safely and reliably replace a protocol biopsy with a noninvasive blood or urinary biomarker for immune surveillance of the transplanted organ? And: what is the role of protocol biopsy in the current era? Both approaches need comparison against the incumbent test, serial (delta) serum creatinine.
Source: Kidney International - Category: Urology & Nephrology Authors: Tags: Controversies in Nephrology Source Type: research